Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Phio Pharmaceuticals Corp. (PHIO)

3.51   -0.52 (-12.9%) 05-31 11:52
Open: 3.59 Pre. Close: 4.03
High: 3.59 Low: 3.38
Volume: 129,571 Market Cap: 5(M)

Technical analysis

as of: 2023-05-31 11:18:53 AM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 6.33     One year: 8
Support: Support1: 3.1    Support2: 2.58
Resistance: Resistance1: 5.42    Resistance2: 6.84
Pivot: 3.99
Moving Average: MA(5): 3.9     MA(20): 3.99
MA(100): 5.27     MA(250): 6.45
MACD: MACD(12,26): -0.2     Signal(9): -0.2
Stochastic oscillator: %K(14,3): 14.3     %D(3): 16.9
RSI: RSI(14): 41.9
52-week: High: 12.27  Low: 3.1
Average Vol(K): 3-Month: 600 (K)  10-Days: 2,877 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ PHIO ] has closed above bottom band by 16.6%. Bollinger Bands are 14.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 4.11 - 4.13 4.13 - 4.15
Low: 3.76 - 3.79 3.79 - 3.82
Close: 3.98 - 4.03 4.03 - 4.07

Company Description

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression for use in ACT; and PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for use in ACT. It has collaborations with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.

Headline News

Wed, 31 May 2023
CTLA-4 Inhibitors Clinical Trial Pipeline: DelveInsight Highlights ... - PR Newswire

Wed, 31 May 2023
Phio Pharmaceuticals slides on equity offering (NASDAQ:PHIO) - Seeking Alpha

Wed, 31 May 2023
Phio Pharmaceuticals Shares Drop 16% After Stock Offerings Price - MarketWatch

Wed, 31 May 2023
Phio Pharmaceuticals Announces $4 Million Concurrent Registered ... - PR Newswire

Fri, 26 May 2023
Soligenix Receives Compliance Confirmation from Nasdaq - Best Stocks

Thu, 25 May 2023
Should You Sell Phio Pharmaceuticals Corp (PHIO) Stock Thursday Morning? - InvestorsObserver

Financial Analysis

Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 2 (M)
Shares Float 0 (M)
% Held by Insiders 1.1 (%)
% Held by Institutions 3.1 (%)
Shares Short 30 (K)
Shares Short P.Month 19 (K)

Stock Financials

EPS -10.86
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 9.52
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) 0
Return on Equity (ttm) 0
Qtrly Rev. Growth 0
Gross Profit (p.s.) -0.11
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)

Stock Valuations

PE Ratio -0.32
PEG Ratio 0
Price to Book value 0.36
Price to Sales 0
Price to Cash Flow 0

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.